1-phenyl-2-decanoylamino-3-morpholino-1-propanol has been researched along with Chronic Illness in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fujimaki, T; Hisaki, H; Kubota, M; Masuda, H; Nakagomi, T; Nakane, M; Nakayama, H; Okazaki, T; Tamura, A | 1 |
1 other study(ies) available for 1-phenyl-2-decanoylamino-3-morpholino-1-propanol and Chronic Illness
| Article | Year |
|---|---|
L-PDMP improves glucosylceramide synthesis and behavior in rats with focal ischemia.
Topics: Animals; Behavior, Animal; Brain Ischemia; Ceramides; Cerebral Cortex; Cerebrosides; Chromatography, Gas; Chronic Disease; Enzyme Inhibitors; Glucosylceramidase; Glucosylceramides; Glycosphingolipids; Infarction, Middle Cerebral Artery; Injections, Intraperitoneal; Male; Maze Learning; Memory; Morpholines; Rats; Rats, Sprague-Dawley; Spatial Behavior; Sphingomyelins | 2008 |